KM Research Hub
← 返回论文库
待处理 入排:待复核 图源:待检查 入排置信度 0.45

Dynamic Circulating Tumor DNA Methylation Monitoring Guiding Postoperative Surveillance in Nonmetastatic Colorectal Cancer: A Prospective, Randomized, Phase III FIND Trial.

Shaobo Mo, Chaoqiang Zhou, Maoguang Ma, Wenqin Luo, Yaqun Li, Ping Lu, Peiyuan Tang, Yaqi Li, Xiaoji Ma, Xiang Hu, Chunliang Cheng, Jiajun Yang, Changhua Zhuo, Jinliang Jian, Cheng Yu, Jinhuo Ding, Chaoxia Xiong, Fei Jiang, Rongrong Mu, Zhuo Lu, Jiayi Yu, Shengnan Jin, Ju Luan, Xinxiang Li, Sanjun Cai, Hai Zou, Yiwei Li, Qingguo Li, Fangqi Liu, Chunming Ding, Junjie Peng

J Clin Oncol JCO2503009

PMID42525894
PMCID-
DOI10.1200/JCO-25-03009
发表日期2026-07-29
入排依据:The record describes a randomized, phase III, human oncology trial with primary results. However, it is excluded because (1) the intervention is a diagnostic/surveillance strategy (ctDNA-guided monitoring) without a drug-containing arm, and (2) the primary efficacy endpoint is not a time-to-event outcome but a categorical proportion of patients receiving therapy. Therefore, it does not meet the required criteria for inclusion.
摘要

摘要

PURPOSE: We hypothesized that a dynamic surveillance strategy guided by circulating tumor DNA (ctDNA) methylation would increase the rate of curative-intent therapy for recurrence in patients with nonmetastatic colorectal cancer (CRC) after curative resection. METHODS: The FIND trial (ClinicalTrials.gov identifier: NCT05904665) is a prospective, multicenter, randomized, phase III study. Patients with nonmetastatic CRC were randomly assigned to ctDNA-guided surveillance or standard computed tomography (CT)-based monitoring. In the ctDNA-guided group, a positive ctDNA result triggered immediate CT imaging; if negative, bimonthly CT continued alongside quarterly ctDNA testing. After two consecutive ctDNA-negative results, imaging reverted to standard frequency. The primary end point was the proportion of patients with recurrence receiving curative-intent metastasis-directed therapy. RESULTS: Among 584 eligible patients (289 ctDNA-guided, 295 control) in the modified intention-to-treat population, with a median follow-up of 23.3 months, recurrence rates were similar (18.0% v 18.6%, P = .919). The ctDNA-guided group had a significantly higher rate of curative-intent treatment (48.1% v 23.6%, relative risk 2.03, P = .008). The median time to clinical recurrence was significantly shorter in the ctDNA-guided group than in the control group (9.5 v 13.4 months; P < .001), representing a lead time of 3.9 months. Among recurrences confined to the liver and/or lungs, the ctDNA-guided group showed higher curative resection rates (42.3% v 18.2%, P = .002). These patients had more favorable hepatic metastatic features: fewer lesions (≤3: 75.0% v 28.6%, P = .005), smaller tumor size (≤3 cm: 90.0% v 57.1%, P = .033), and more unilobar disease (80.0% v 28.6%, P = .002). CONCLUSION: ctDNA methylation-guided dynamic surveillance improves the rate of curative-intent therapy for recurrence in patients with initially nonmetastatic CRC through earlier detection of resectable metastases, pending validation of long-term survival benefit in future analyses with mature data.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。